Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) just unveiled an update.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Sodium Bicarbonate Injection in ampoule form. This development is significant as the drug is used in treating metabolic acidosis, alkalinization of urine, and intravenous intoxication by certain drugs, potentially enhancing the company’s market position and offering new treatment options.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is engaged in creating medical solutions, with a market focus on drug production and registration.
YTD Price Performance: -3.70%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.24B
See more data about 2005 stock on TipRanks’ Stock Analysis page.